melanoma
Merck’s melanoma vaccine impresses
November 19, 2013Research and Development, Sales and Marketing MK-3475, Merck, Roche, melanoma
Merck has posted impressive results for its new melanoma vaccine MK-3475 as it looks to vie for a place in …
Yervoy setback in prostate cancer
September 16, 2013Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer
GSK cancer vaccine fails in Phase III
September 5, 2013Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III
GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …
GSK’s skin cancer pill Tafinlar gets EMA approval
September 3, 2013Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma
GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …
Vical melanoma drug dropped
August 13, 2013Research and Development, Sales and Marketing Vical, allovectin, melanoma
Vical has abandoned trials of a late-stage drug for the deadliest form of skin cancer after the treatment failed to …
Eight in ten survive skin cancer
July 22, 2013Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer
The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …
FDA seeks manufacturing data for GSK’s trametinib
May 2, 2013Manufacturing and Production FDA, GSK, melanoma
GlaxoSmithKline’s melanoma drug candidate trametinib has been delayed in the US by an FDA request for more information on its …
Melanoma breakthrough for Merck
April 26, 2013Research and Development, Sales and Marketing FDA, Merck, lambrolizumab, melanoma
Merck’s pipeline has been given a boost by an FDA decision to designate early-stage investigational drug lambrolizumab as a breakthrough …
GSK submits melanoma drugs for regulatory approval
August 3, 2012Sales and Marketing FDA, GSK, NDA, Zelboraf, melanoma, oncology
GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
GSK starts combination trial for melanoma
May 30, 2012Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma
GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs. The firm will combine dabrafenib, its …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
European approval for Roche’s Zelboraf
February 20, 2012Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma
Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma. Zelboraf (vemurafenib) is now available in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
